The Effectiveness of Newer Beta-Lactams for the Treatment of Antimicrobial-Resistant Gram-Negative Meningitis

Area of Science:

• Infectious Diseases
• Pharmacology
• Neuroscience

Background:

• Gram-negative bacterial infections with difficult-to-treat resistance (DTR) present significant therapeutic challenges.
• Central nervous system infections, such as bacterial meningitis, are particularly complex due to limited antibiotic penetration into cerebrospinal fluid and brain parenchyma.
• Limited effective antibiotic options exist for DTR gram-negative infections.

Purpose of the Study:

• To review host and drug factors influencing antibiotic effectiveness in bacterial meningitis.
• To examine preclinical and clinical data for newer beta-lactam agents against DTR gram-negative meningitis.

Main Methods:

• Literature review of host and drug factors affecting antibiotic efficacy.
• Analysis of preclinical and clinical studies on specific newer beta-lactam agents.
• Evaluation of cerebrospinal fluid and brain parenchyma penetration data.

Main Results:

• Several newer beta-lactam agents (cefiderocol, ceftazidime-avibactam, ceftolozane-tazobactam, imipenem-cilastatin-relebactam, meropenem-vaborbactam, sulbactam-durlobactam) demonstrate activity against DTR gram-negatives.
• Antibiotic penetration into the central nervous system is a key determinant of treatment success.
• Data supporting or refuting the use of these agents for bacterial meningitis varies.

Conclusions:

• Effective management of DTR gram-negative meningitis necessitates considering antibiotic CNS penetration.
• Further research and clinical data are needed to optimize treatment strategies for these challenging infections.
• Newer beta-lactam agents offer potential therapeutic options but require careful evaluation for CNS efficacy.